Institut National de la Santé et de la Recherche Médicale, U1015, Villejuif, France.
Ann N Y Acad Sci. 2010 Oct;1209:99-108. doi: 10.1111/j.1749-6632.2010.05763.x.
The concept of immunogenic chemotherapy that has recently emerged relies upon the capacity of a cytotoxic compound to trigger a cell-death modality. This modality elicits cross-priming by dendritic cells of tumor antigen-specific T cells that will contribute to the tumoricidal activity of the compound and protect the host against relapse. In contrast, most anticancer drugs elicit nonimmunogenic apoptosis that is not accompanied with an immunizing property. This review will discuss some molecular and metabolic changes required at the level of the tumor that must engage key pathways at the level of the host for the induction of Tc1 polarized-protective T cell responses during chemotherapy. We will summarize the immune adjuvants that can boost the immunogenicity of cell death to augment the efficacy of chemotherapy.
最近出现的免疫化学疗法的概念依赖于细胞毒性化合物触发细胞死亡模式的能力。这种模式通过树突状细胞引发肿瘤抗原特异性 T 细胞的交叉呈递，这将有助于化合物的肿瘤杀伤活性，并保护宿主免受复发。相比之下，大多数抗癌药物引发非免疫性细胞凋亡，不具有免疫原性。这篇综述将讨论肿瘤水平所需的一些分子和代谢变化，这些变化必须在宿主水平上涉及关键途径，以诱导化疗期间 Tc1 极化保护性 T 细胞反应。我们将总结可以增强细胞死亡免疫原性以增强化疗效果的免疫佐剂。
